Ibrutinib force

Without generating a single cent in sales, ibrutinib has already produced at least $835 million in cash for its current and former owners, including $350 million in partnership money for Pharmacyclics Inc. (NASDAQ:PCYC) and $485 million pocketed by Quest Diagnostics Inc. (NYSE:DGX) this month through the sale of its residual royalty stake.